DoD Rare Cancers, Resource and Community Development Award | HT942525RCRPRCDA

FY25 DoD Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) - FAQs

1. What is the FY25 DoD RCRP Resource and Community Development Award (RCDA)?

The Resource and Community Development Award (RCDA) is a U.S. Department of Defense (DoD) grant opportunity that supports projects designed to build shared resources, usable data sets, and community infrastructure for rare cancers research. The overall intent is to strengthen the rare cancers research ecosystem so progress can move faster and more effectively translate into improved patient outcomes.

2. What is the main purpose of this award?

The central purpose is to create platforms, tools, coordinated efforts, and research-enabling resources that can be broadly used and built upon by many researchers and stakeholders, rather than funding a single narrow, hypothesis-driven study.

3. What types of projects are a good fit for the RCDA?

Projects that focus on building shared resources, generating reusable data sets, improving infrastructure for sharing data and materials, and strengthening collaboration networks across rare cancers stakeholders are a strong fit. The award is meant to enable the broader research community by creating resources that multiple groups can access and use.

4. Does the RCDA focus on hypothesis-driven research?

This award is positioned to support resource-building and community infrastructure efforts rather than being limited to a single, narrow hypothesis-driven study. Projects should emphasize creating broadly useful platforms or resources.

5. What bottlenecks in rare cancers research does the program want to address?

The opportunity highlights several major bottlenecks, including limited availability of research and clinical resources, gaps in communication and dissemination, insufficient infrastructure for sharing data and resources, and the need for therapeutics-focused and mechanistic research resources that can accelerate treatment development.

6. What specific research and clinical resources are prioritized?

The program prioritizes proposals that help address shortages of rare cancer resources such as patient tissue collections, cell lines, and tumor models, which are often scarce for rare diseases.

7. What does the program say about communication and dissemination?

It explicitly calls for better communication and dissemination approaches so that findings and outputs are shared more effectively between scientists, clinicians, and patient communities.

8. What does “infrastructure for sharing data and other research resources” mean in this context?

Examples referenced include standardized repositories, harmonized databases, and systems that make it easier to find, access, and reuse rare cancer data and resources. The emphasis is on enabling discoverability and reuse by the broader community.

9. Does the RCDA support resources that help with therapeutics development?

Yes. The program highlights the need for more therapeutics-focused and mechanistic research resources that can inform and speed treatment development, particularly in areas where fundamental understanding is still limited.

10. Is patient advocate engagement required?

Yes. Patient advocate engagement is described as a defining expectation and is not optional or superficial. Partnerships with Patient Advocates must be built into the project from the beginning, including shaping the research question, and must continue throughout the execution of the work.

11. What does the award mean by “community building” as a deliverable?

Community building is treated as a core deliverable. Applicants are expected to propose concrete ways to connect and strengthen networks across researchers, clinicians, and patient groups, rather than operating in isolation.

12. Are applicants expected to plan for sharing project outputs?

Yes. Dissemination is emphasized as something that must be planned up front. Applicants are expected to explain how the resulting platform, data set, or resource will be shared with the scientific and/or clinical community.

13. Are applicants expected to plan for sustainability after the award ends?

Yes. Sustainability is also emphasized as an up-front requirement. Applicants should describe how the resulting resource will remain useful beyond the end of the award period, rather than ending when the funding ends.

14. Is preliminary data required to apply?

No. The program does not require preliminary data, which may make it more accessible for new resource-building efforts or newer collaborations.

15. Can preliminary data be included anyway?

Yes. While not required, preliminary data may be included if it helps demonstrate feasibility, readiness, or proof-of-concept.

16. What is the FY25 budgeting change mentioned for this opportunity?

For FY25, the funding limits are expressed as total costs. That means the cap (when specified in the full announcement) includes both direct costs (project expenses) and indirect costs (institutional overhead). This affects how applicants plan and structure their budgets.

17. Is the award ceiling (maximum budget) provided in the listing?

No. The award ceiling is not specified in the provided listing. Applicants would need to consult the full announcement or related program guidance to confirm the budget cap and any additional constraints.

18. Which agency administers this grant?

Administratively, this is a discretionary grant under the Department of the Army, managed through USAMRAA (U.S. Army Medical Research Acquisition Activity).

19. What is the CFDA number and category for this program?

The program is categorized under science and technology and research and development and is listed as CFDA 12.420.

20. Who is eligible to apply?

Eligibility is listed as unrestricted, which suggests a broad range of applicant types may apply, as long as they meet standard federal requirements.

21. What is the opportunity number for this funding call?

The opportunity number is HT942525RCRPRCDA.

22. What is the application closing date?

The application closing date is October 6, 2025.

23. How many awards does the program expect to make?

The program anticipates making about five awards.

24. What should applicants keep in mind when designing an RCDA project?

Based on the listed expectations, applicants should focus on building broadly usable resources or infrastructure, embed meaningful patient advocate partnerships from the start, include concrete community-building activities, and plan up front for both dissemination and long-term sustainability of the outputs.